MetLife stock has delivered a strong 80.7% total return over the past 5 years, yet the current valuation picture is mixed, with an Excess Returns intrinsic value estimate pointing to material upside while broader checks lean less generous.
- The 80.7% 5 year gain suggests investors have already been rewarded for owning MetLife, so the key issue now is how much upside is left from here.
- Future expectations for MetLife's ability to generate returns on equity above its cost of capital can support the intrinsic value case, while any pressure on underwriting profitability or investment returns may limit how much value the company can create for shareholders.
- The stock screens as about right on earnings multiples, and with a low value score of 2 out of 6 the broader checks do not present MetLife as a clear bargain.
The issue now is whether MetLife's current share price already reflects its Excess Returns potential or if the intrinsic value estimate still leaves a meaningful margin of safety for long term investors.
Compare MetLife's valuation setup with a curated list of other potential opportunities by scanning 45 high quality undervalued stocks, which currently combine quality fundamentals with compressed pricing.
Is MetLife Still Cheap on Excess Returns?
The Excess Returns model evaluates how much profit MetLife can generate above its cost of equity on each dollar of book value. For MetLife, the inputs suggest a company earning a higher return on shareholder capital than it needs to compensate investors for risk.
Book value is $43.03 per share, with a stable book value estimate of $53.18 per share based on analyst projections. Stable EPS is modeled at $8.42 per share, while the cost of equity is $3.99 per share. That gap leaves an excess return of $4.43 per share, supported by an average return on equity of 15.83%. These assumptions produce an Excess Returns intrinsic value estimate of $169.91 per share, which implies the stock is trading at about a 44.0% discount to this value.
On this Excess Returns view, MetLife stock appears undervalued relative to the cash generation implied by its projected returns on equity.
Our Excess Returns analysis suggests MetLife is undervalued by 44.0%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.
Where Does MetLife Sit on Earnings?
The P/E ratio is a reasonable way to look at MetLife because earnings power is central to how investors usually value large insurers. On this measure, MetLife trades on a P/E of 17.6x, which is above the broader insurance industry average of 11.2x and also above the peer group average of 14.6x.
A tailored fair P/E for MetLife of 16.1x captures factors such as its earnings profile, size and sector risks. That sits only slightly below the current 17.6x, so the stock trades at a modest premium to what this model suggests rather than at an extreme level. For investors, that points to a valuation that already recognises some of MetLife's strengths but does not look wildly stretched on earnings alone.
On the P/E multiple, MetLife stock looks roughly fairly valued with only a small premium to its modelled fair level.
See what the numbers say about this price — find out in our valuation breakdown.
The MetLife Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the valuation puzzle for MetLife leaves off by spelling out which expectations for MetLife's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each narrative sets out the assumptions that underpin its fair value view so you can compare them with MetLife's reported results over time.
Share a narrative on MetLife and add your voice to the Simply Wall St community with a clear, number-driven case on where its growth, margins and execution go from here. You can then track how your thesis holds up as new results are reported over time.
Do you think there's more to the story for MetLife? Head over to our Community to see what others are saying!
The Bottom Line
MetLife looks cheap on the Excess Returns intrinsic value estimate, while the P/E view points to a stock that is priced about right compared with peers. That split likely reflects different weight on cash generation and capital intensity versus current earnings and sentiment. Broader checks lean cautious, so the key question is whether MetLife can keep earning returns on equity that comfortably exceed its cost of capital. If that holds, the current discount may look attractive. If profitability or investment returns come under pressure, the stock could be closer to fully valued than the intrinsic value model implies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com